Arcutis Takes On Incyte In Atopic Dermatitis With New Zoryve Nod
A third US FDA approval for its skin drug is putting Zoryve into a strong position to become the preferred topical brand in dermatology, claims CEO Frank Watanabe.
A third US FDA approval for its skin drug is putting Zoryve into a strong position to become the preferred topical brand in dermatology, claims CEO Frank Watanabe.